Company intelligence / Profile preview

LusBio

White Plains, New York, United Statesadvancedautobat.com ↗

Ownership: Private
Development stage: Other

Overview

The company's lead product, ClearStrand-ASD—a non-invasive diagnostic aid using hair samples—has received FDA Breakthrough Device designation and can identify ASD-associated biomarkers in children as young as one month. It has launched commercially. Additional diagnostics are under development targeting ALS, ADHD, schizophrenia/psychosis.

Therapeutic areas: PsychiatryNeurology
Modalities: Diagnostic biomarker assay (exposomics-based)AI-powered biomarker discovery platform
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on LusBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LusBio.

Explore the full profile